Company intelligence / Profile preview

Chengdu Ori Pharmaceutical

Chengdu, Sichuan, China

Ownership: Private
Development stage: Other

Overview

Chengdu Ori-Bio Pharmaceutical is a clinical-stage biotechnology company focused on the discovery and development of innovative peptide-based therapeutics for metabolic and endocrine diseases. The company leverages its proprietary peptide engineering platform to create long-acting and multi-targeting analogs, particularly focusing on GLP-1, GIP, and Glucagon receptor agonists. Their lead programs target high-prevalence conditions such as type 2 diabetes, obesity, and MASH (NASH). Ori-Bio aims to improve patient outcomes through enhanced efficacy and better tolerability profiles compared to existing treatments.

Therapeutic areas: EndocrinologyGastroenterologyMetabolic Disorders
Modalities: PeptidesBiologicSmall molecule
Industry: Biotech

Drug pipeline

1 asset

ORIC-1940

Unknown

Beyond the preview

Go deeper on Chengdu Ori Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu Ori Pharmaceutical.

Explore the full profile